Therapies for Axial Disease in Psoriatic Arthritis. A Systematic Review
Prevalence rates for axial involvement in psoriatic arthritis (PsA) vary from 40% to 74% depending upon criteria for diagnosis. In the absence of trial evidence to assess axial involvement in PsA, the GRAPPA group, by consensus, has suggested that outcome measures and therapies for axial disease in ankylosing spondylitis (AS) be used. This systematic review addresses the management of axial disease in PsA, and provides treatment recommendations based on the AS literature. (First Release May 15 2006; J Rheumatol 2006;33:1431–4)
Key Indexing Terms:
From the Department of Medicine, University of Queensland, Cotton Tree, Australia.
P. Nash, MBBS (Hons), FRACP.
Address reprint requests to Dr. P. Nash, Department of Medicine, University of Queensland, PO Box 59, Cotton Tree, Australia. E-mail: email@example.com